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New therapeutic alternatives to fight against the spread of HIV-1 are based on peptides designed 
to inhibit the early steps of HIV-1 fusion in target cells. However, drawbacks such as: 
bioavailability, short half-life, rapid clearance and poor ability to cross the physiological barriers 
make such peptides unattractive for the pharmaceutical industry. Here we developed, optimized 
and characterized polymeric nanoparticles (NPs) coated with glycol chitosan (GC) to incorporate 
and release an HIV-1 fusion inhibitor peptide (E1), inside the vaginal mucosa. The NPs were 
prepared by a modified double emulsion method and optimisation was carried out by a factorial 
design. In vitro, ex vivo and in vivo studies were carried out to evaluate the optimized 
formulation. The results indicate that the physicochemical features of these NPs enable them to 
incorporate and release HIV fusion inhibitor peptides to the vaginal mucosa before the fusion 






1.  INTRODUCTION 
 
The GB virus C (GBV-C) is a non-pathogenic virus identified and classified as belonging to 
the flaviviridae family1. GBV-C has attracted considerable research attention because it has been 
associated with a decrease in the morbidity and mortality rate of individuals co-infected with 
HIV-1. Furthermore, a meta-analysis found that HIV patients with GBV-C viraemia survive 
longer than those without viraemia2. GBV-C is a lymphotropic virus that replicates in human 
peripheral blood mononuclear cells (PBMCs), including B and T lymphocytes (CD4+ and CD8+ 
subsets) 3. PBMC co-infection with GBV-C and HIV inhibits HIV replication4.  
The E1 and E2 envelope proteins of GBV-C are associated with the inhibition HIV-1 
replication in vitro. These class II fusion proteins are non-helical and have a fusion peptide 
within internal loop structures, far from the N-terminus 5. Several studies have described and 
characterized fragments belonging to GBV-C envelope proteins that may be involved in 
inhibiting HIV-1 fusion to cells. The inhibition capacity of these peptides has been tested in 
various biological systems including blood cells, lipids mixtures and Langmuir monolayers 6–8. 
These assays have shown that: (a) E2-derived peptides bind to gp4, preventing oligomerisation 
of the HIV-1 fusion peptide on the membrane, thus inhibiting its destabilisation, which is 
essential for HIV-1 fusion to the cell membrane; and (b) E1-derived peptides may bind in a 
highly conserved region on gp41 (fusion peptide) before pre-hairpin formation, which inhibits 
HIV fusion and entry 9,10. Some authors have proposed using these peptides to develop new 
strategies to fight against HIV-1 11–13, since these inhibitor peptides specifically target the sites 
where the earlier steps of HIV fusion take place. However, they present shortcomings, such as 
low oral bioavailability, a short half-life and rapid clearance, which render them unsuitable for 
the pharmaceutical industry 14. 
The virus is mainly transmitted vaginally and rectally, but the pH and enzymes of the vaginal 
fluid lining the epithelium present a major obstacle preventing antiretroviral drugs and 
biomolecules such as peptides from reaching the vaginal epithelium. These drawbacks may be 
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overcome by using nanoparticle (NP) delivery systems, which entrap large molecules such as 
proteins and polypeptides and release them to the target tissue without damaging it. 
Currently there are over 50 molecules which are candidates to be anti-HIV microbicides and 
which are in the pre-clinical phases, and another 12 in clinical phases. The most frequently used 
alternatives for microbicide treatment are the polymer NPs. The NPs manufactured with 
polymers, such as PLGA, are being investigated, as these devices can overcome the typical 
problems of drugs such as the biological half-life, conformational stability, physio-chemical 
stability, solubility and immunological response 15. 
 In addition to PLGA, polymers, which act against the transmission of the virus on their own, 
have been investigated. This is the case of anionic polymers, which stick to the viral envelope 
and block the entrance of the virus into the target cell. Along these lines, the fabrication of 
microbicides has been proposed. Their formulation is to be the combination of therapeutic 
effects, from the transporter material of which they are made, specifically polyanionic materials, 
and an anti-retroviral drug 16. 
In the light of the facilities that the vaginal mucosa offers for treatment with drugs, several 
studies have been carried out using NPs to encapsulate and release anti-HIV drugs into the 
vaginal mucosa17. For example, the anti-retroviral drug Tenofovir has been released in a sustained 
manner from nanofibers with special physio-chemical and surface properties that guarantee the 
safety and integrity of the mucosa 18.  
Combined therapy based on the development of NPs is another alternative being considered as 
an important platform in the prevention of HIV. Some authors propose developing an anti-HIV 
microbicide looking for an approach to different problems such as the maintenance of the 
biological conditions of the vaginal mucosa, (pH, bacterial flora) as well as how to prevent the 
viral infection at the same time throughout the invasive stages 19.  
Another aspect that has been studied is the benefits of the NPs in the development of anti-HIV 
microbicides. This is because these systems offer versatility in the modulation of the drug 
release: a slow and sustained liberation of the drug is of vital importance to its acceptance 20 
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Nanoparticle systems offer several specific advantages over other delivery systems. For 
instance, they can improve the stability of peptides and maintain their physicochemical 
properties. They can easily be manipulated to prevent premature release. They may increase the 
effectiveness and reduce the side effects of the drugs they carry and they can be modified with 
surface ligands to achieve a specific target 21. In addition, NPs made with polyesters such as poly 
(D, L-lactic-co-glycolic acid) (PLGA) offer the further advantages of biocompatibility, 
biodegradability and non-toxicity 22. As for PLGA, they have been investigated for their ability to 
enhance tissue permeability. Leading on from this, it has been described that PLGA 
nanoparticles do not compromise the cell monolayer integrity23,24 . 
PLGA polymers have been approved by the Food and Drug Administration (FDA) and used as 
colloidal carriers for controlled drug release, 25 and this is the reason why PLGA NPs have been 
used as drug carriers for topical administration mixed with polysaccharides such as chitosan 26,27. 
Chitosan is a chitin derivative that enhances permeation through the vaginal mucosa, and it has 
been widely used in manufacturing of nanoparticles. It has excellent biocompatibility and little 
toxicity, probably because of its natural origin. Additionally, it prolongs residence time in tissues 
and has been widely and effectively used in the transport of macromolecules such as peptides 
and proteins. This is because chitosan adheres to mucus and enhances the efficient permeation of 
NPs loaded with peptides and proteins 28. Another advantage described by some authors is that 
polymeric nanoparticles coated with chitosan substantially increase the bioavailability and 
efficacy when administered by via vaginal route 29,30.  
Techniques based on double emulsions have been the most commonly used method for the 
encapsulation of hydrophilic molecules such as peptides and proteins. This method has 
significant advantages over other techniques such as drying by pulverization (spray drying), and 
supercritical fluid. For example, the latter method has two principal drawbacks: (a) the poor 
performance of the powder obtained (low powder yield), and (b) the agglomeration of particles 
that can lead to the loss of the biological activity of the biomolecule 31. In the administration 
route, the drying method has been used for the fabrication of particles when they are intended to 
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be administered by inhalation. However, the double emulsion method has been successfully used 
in the fabrication of particles for topical administration and thus has become the most suitable 
method in the creation of NPs loaded with anti- HIV biomolecules for the vaginal and rectal 
delivery 32.  
For all the reasons indicated above, and due to the drawbacks of the other methods, we have 
considered the double emulsion method as the best choice to deliver the anti-HIV synthetic 
peptide, that has been defined in our group 9, into the vaginal tissue. The preparation of PLGA-
chitosan NPs by means of the double emulsion method for the peptide encapsulation is valid. 
Glycol-chitosan (GC) coated PLGA-NPs were developed with the capacity to incorporate an 
HIV-1 inhibitor peptide (E1) and then released into porcine vaginal epithelium. To this end, NP 
preparation was optimized by a factorial design. Transmission electron microscopy (TEM), X-
ray and IR assays were used to analyze morphological and physicochemical properties. In vitro, 
ex vivo and in vivo assays were performed with optimized and characterized formulations. 
Interactions between E1NPs and HeLa cells expressing HIV-1 envelope proteins were analyzed 
by flow cytometry. In addition, ex vivo and in vivo permeation studies were performed using 
porcine vaginal mucosa as a animal model. 
The novelty of the paper lies in the preparation of a formulation based on a fusion inhibitor 
peptide that has been previously described by our group, as well as in vitro, ex vivo and in vivo 
studies, and that it is potentially viable as a microbicide 9. As has recently been described, 
antiretroviral-based strategies for HIV prevention have shown inconsistent results in women 33. 
Regarding clinical trials on women, the efficacy of vaginal-applied Tenofovir gel to prevent HIV 
infection ranged from 0% in FACTS trials to 39% in CAPRISA trials. Thus, the study of other 
formulations based on new fusion inhibitors that impede the entry of the HIV-1 into the host 






2.  MATERIALS AND METHODS 
The chemicals and materials used in this study are described in the Supplementary Material 
section.  
2.2 Experimental Section 
2.2.1. Peptide synthesis 
The E1 peptide was synthesised by the Fmoc/tBu strategy of solid-phase peptide synthesis 
(SPPS) using a NovaSyn® TGR resin (500 mg, 0.25 meq/g). Couplings were achieved by 
HATU/DIPEA activation with a molar excess of Fmoc-amino acids (3 meq/g). The E1 peptidyl 
resin was labelled with 5(6)-carboxyfluorescein. E1 and E1-FAM were then purified by a 
semipreparative high-performance liquid chromatography (HPLC) method. Peptide synthesis is 
described in more detail in the Supplementary Material section. 
 
2.2.2. Preparation of Nanoparticles  
The Nanoparticles (NPs) were prepared using a modified double emulsion method 34–36. Before 
optimisation, several trial batches were carried out to determine the maximum entrapment 
efficiency (EE) rate of the peptide and a suitable NP diameter that reached the vaginal epithelium 
(between 200 and 300 nm). The variables considered for NPs optimization were: (a) the 
poly(lactic-co-glycolic acid) (PLGA) polymer concentration (mg); (b) polyvinyl alcohol (PVA) 
concentration (mg); (c) E1 concentration (mg); (d) the inner aqueous phase (IAP) composition 
and volume; and (e) the pH of the IAP. Resomer® RG 503 H, Poly (D, L-lactide-co-glycolide) 
(PLGA) was selected as the most appropriate polymer since the NPs made with this polymer 
incorporated more than 50% of the peptide. NPs with E1 and empty NPs were prepared 
separately. The preparation and purification of the NPs were carried out following the 
methodology described in Ariza-Sáenz et al., 37 with some modifications: 1.5 mg of E1 peptide 
was solubilized in a mixture of Hepes 50mM (pH 7.2) and acetonitrile (ACN) forming an IAP. 
Next, 50 mg of PLGA was dissolved in 1 ml of dichloromethane obtaining the organic phase 
(OP). Briefly, a primary emulsion water-in-oil was formulated by emulsifying the IAP with OP 
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(50 W, 30 sec). 0.05 % (w/v) of Glycol chitosan (GC) was dissolved in 2.5 % (w/v) polyvinyl 
alcohol (PVA) acidic solution (pH 4.2) and stirred magnetically. Afterwards, secondary emulsion 
(water/oil/water) was obtained by adding the primary emulsion drop wise to the PVA solution 
containing GC, followed by probe sonication (50 W, 60 sec). The resultant emulsion was stirred 
vigorously over-night to evaporate the organic phase and to obtain the NPs. Once the NPs had 
been fabricated, the suspension was deposited in a centrifuging tube of polyacrylate and 
centrifuged at 15000 rpm during 15 min at 4º C and washed twice with Milli-Q water to remove 
excess PVA-GC and free peptide. Supernatants were storage to determine the free peptide by 
HPLC UV-VIS validated method (see supplementary materials section). 
 
2.2.3.  Central composite factorial design 
A factorial design was applied to determine the minimum number of experiments required for 
optimized E1NPs synthesis. A three-factor, five-level central composite rotatable design 2!+star 
38, was used to evaluate the main effects and interactions of three factors on average particle size 
(Z-Ave), polydispersity (PI) and EE. The three factors selected, E1 concentration (X1), IAP 
volume (X2) and polymer concentration (PLGA) in the organic phase (X3), were studied at five 
different levels coded as −α, −1, 0, 1 and +α. The value for alpha (1.682) was calculated to 
obtain rotatability in the design. The codes and values of the variables are given in Table S7 in 
the supplementary materials section. According to the central composite design matrix generated 
by the Statgraphics Plus version 5.1 software (Sigma Plus), a total of 16 experiments were 
required, including 8 factorial points, 6 axial points and 2 replicated center points for estimating 
the pure error sum of squares (Table S8 supplementary materials section). The effects and 
interactions between the variables or factors were calculated. To determine the effect of a factor 











 where ∑x (+) is the sum of the factors at their highest level (+1), ∑x (−) the sum of the factors 
at their lowest level (−1) and n/2 is half of the number of measurements used in the calculation. 
The interactions between the factors were also evaluated. To estimate an interaction between two 
factors, the effect of the first factor at the lowest level of the second one had to be estimated, 
subtracting it from the effect of the first factor at the highest level of the second one. An 
interaction between two factors is symbolized as factor 1: factor 2.  
The experimental responses studied were the results of the individual influence and the 
interactions of the three independent variables. The responses were therefore modelled by the 
following full second-order polynomial equation: 
 
𝑌 = 𝛽! + 𝛽!𝑋! + 𝛽!𝑋! + 𝛽!𝑋! + 𝛽!!𝑋!! + 𝛽!!𝑋!!+𝛽!!𝑋!! + 𝛽!"𝑋!𝑋! + 𝛽!"𝑋!𝑋! + 𝛽!"𝑋!𝑋! (2) 
 
where Y is the measured response, β0 the intercept, β1, β2 and β3 the linear coefficients, β11, β22 and 
β33 the squared coefficients, β12, β13 and β23 the interaction coefficients, and X1, X2 and X3 the 
independent variables. 
Statgraphics Plus version 5.1 (Sigma Plus) was used for the statistical analysis of the data. To 
determine the significance of the effects and interactions between them, analysis of variance 
(ANOVA) was performed for each parameter. A p value less than 0.05 was considered 
statistically significant.  
 
2.2.4.  Physicochemical characterization of NPs  
The physicochemical characterization of the NPs was achieved by measuring the Z-Ave and 
PI. NP surface charge was measured as the zeta potential (ζ) and the EE percentage of the 
peptide loaded into the NPs was determined indirectly by determining the concentration of the 
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peptide that was not incorporated into the NPs. In short, after centrifugation of NPs, 50 µl of the 
supernatant that containing the peptide was injected into HPLC system equipped with a C18 
column and an absorbance dual detector (Waters 2487). Mobile phases applied were: ACN /TFA 
0.05% and Milli-Q water /TFA 0.05 %. Separation was performed by applying linear gradient 
from 5 % to 95 % (ACN/TFA 0.05 %) over 20 min at a flow rate of 1 ml/min. Peptide detection 
was performed by absorbance at 265 nm. Peptide concentration was calculated using the 
following equation.  
𝐸𝐸 % = !"#$% !"#$%& !" !"!#$%"!!"## !"!#$%"
!"!#$ !"#$%& !" !"!#$%"
 𝑥 100 (3) 
 
2.2.5.   X-Ray and FTIR studies  
The physical state of the peptide in the NPs and the possible interactions between the peptide 
and the PLGA were determined by X-ray and Fourier transform infrared (FTIR) spectroscopy. 
The E1NPs suspension was centrifuged, and the pellet that contained 1.2 mg of peptide was 
dried under vacuum conditions before being dried to a constant weight in a desiccator.  
 
2.2.5.1.   Fourier transform infrared studies 
The FTIR spectra of E1NPs and their compounds (peptide, PLGA and GC) were obtained 
using a Thermo Scientific Nicolet iZ10 FTIR spectrometer with a diamond attenuated total 
reflectance (ATR) (DTGS detector; Nichrome source; KBr beamsplitter), with a total of 32 scans 
(resolution, 4 cm−1). The spectra were collected and manipulated using the OMNIC (version. 
7.3) software supplied by the manufacturer of the spectrometer. The spectra of each sample were 
collected in triplicate. The FTIR spectra of E1NPs were obtained using a deuterated-triglycine 






2.2.5.2.   X-ray studies 
The X-ray analyses were carried out to evaluate either crystalline or amorphous state of NPs. 
X-ray powder diffractograms were recorded on a Siemens D500 system (Karlsruher, Germany) 
using Cu Kα radiation (45 kV, 40 mA, λ= 1.5418 Å). The range scan was (2θ) from 2º to 60º for 
a step size of 0.026º and a measuring time of 200 seconds/step. 
 
2.2.6.  Transmission electron microscopy  
The morphology of E1NPs was evaluated by transmission electron microscopy (TEM). The 
E1NPs collected by centrifuging were diluted in Milli-Q water, and 10 µl of the sample (E1NPs) 
were placed onto the copper EM grids and stained with a 2% (w/v) uranyl acetate solution. After 
1 minute, the sample was washed with ultra-purified water and the excess removed using a filter 
paper. The sample was dried and analyzed. 
 
2.2.7.  In vitro  release studies  
To estimate the profile of E1 release from the NPs, Franz diffusion cells (FDC-400) with a 
diameter of 18 mm were used. E1-loaded NPs or non-formulated E1 (1 ml) were placed in the 
donor compartment. The receptor compartment was filled with 5 ml of the receptor medium (1 
M phosphate buffer, pH 7.4) and a dialysis cellulose membrane was placed between the donor 
and receptor compartments of the Franz cells. Sink conditions were maintained throughout the 
experiment for 24 hours. At predetermined time points, 100-µl aliquots were withdrawn for E1 
determination and replaced with fresh medium. A successfully validated HPLC-ESI-MS/MS 
method was used to determine the amount of E1 released. The concentration of E1 released was 
measured as previously described in section 2.4. Results are presented as the mean ± SD of three 
replicates. The detection methods were validated following the ICH guidelines 39. The parameters 
studied and the results obtained, are summarized in supplementary materials section.  
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To determine the mechanism of drug release, three different kinetic models (First order, 
Higuchi and Korsmeyer-peppas) were used to fit the experimental data obtained in the E1 release 
experiments 40 
First order kinetics:   𝑄! =  𝑄!(1− 𝑒!!")    (4) 
Higuchi:  𝑄! = 𝐾!𝑡
!
!     (5) 
Peppas-Korsmeyer: 𝑄! =  𝐾!𝑡!     (6) 
Where: 
 𝑄!  is the cumulative amount of peptide release at time t; t is time in hours, 𝐾! Higuchi 
constant, K is the first-order release constant, 𝐾! is kinetic constant and n is the diffusional or 
release exponent, that could be used to characterize the different release mechanism n < 0.43 
(Fickian diffusion), 0.43 < n < 0.85 (anomalous transport) and n ≥ 0.85 (case II transport; i.e. 
zero-order release. 
2.2.8.  Stability assays 
A technology based on the analysis of multiple dispersions of light was used to predict the 
short-term physical stability of the developed formulations. Turbiscan Lab® (Formulaction, 
L’Union, France) is an optical instrument that characterises concentrated emulsions and 
dispersions, detecting destabilisation phenomena much earlier than the operator’s naked eye, 
especially for concentrated and optically thick media. One of the principal advantages of using 
Turbsican Lab® in the physical stability of the NPs is that the instrument is well suited for 
working without dilution at high concentrations (up to 95 % v:v), and over a wide particle size 
range: 10 nm - 1 mm.41 
Two undiluted formulations were mixed and placed on a cylindrical glass cell, which was 
scanned by a reading head. The scan was achieved with a pulsed near-infrared light source (λ = 
880 nm) and two synchronous optical detectors. The transmission (T) detector receives the light 
transmitted through the sample (0º from the incident radiation), while the backscattering (BS) 
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detector receives the light backscattered by the sample (135º from the incident radiation) 41. The 
formulation was milky and opaque; therefore, only BS profiles were used to evaluate the 
physicochemical stability of E1NPs. The reading head gathered the BS data every 40 µm for 24 
hours. These measurements were performed on samples stored for up to 7 days at 4 ºC. These 
parameters are represented by a curve showing the percentage of BS as a function of the sample 
height in millimeters. The acquisitions were repeated, generating a superimposition of sample 
fingerprints that then demonstrated the stability or instability of the sample. 
 
2.2.9.  Stability of E1 and E1NPs in human serum 
A suspension of E1-NPs in Hanks Balanced Salt Solution (HBSS) at a peptide concentration of 
approximately 1mg/ml was incubated at 37 ºC in the presence of 90 % human serum for 24 h. At 
different incubation times (30 min, 1 h, 2 h, 4 h, 8 h and 24 h), 50 µl aliquots were treated with 
200 µl of methanol to precipitate serum proteins. After 30 min of centrifugation at 14000 rpm at 
4 ºC in a centrifuge Mikro 200R Hettich (DJB Labcare Ltd, Buckinghamshire, UK), the 
supernatant was analysed by RP-HPLC to calculate the percentage of intact peptide in the 
sample. The analysis of the peptides was carried out on a 1260 Infinity chromatograph (Agilent 
Technologies, Santa Clara, CA, USA) with a Poroshell 120 EC-C8 (Agilent, 2.7 μm, 4.6×100 
mm). An isocratic method of 55 % of water with 0.05% TFA and 45 % of acetonitrile with 0.05 
% TFA was used for analysing the samples. 
 
2.2.10.  Uptake assays 
For the uptake assays, NPs were prepared with 125 µg of E1-FAM. Studies were performed 
using endothelial cells (HeLa-env donated by Dr Blanco from the Fundació IRSI) that expressed 
high levels of the Gag, Env, Tat, Rev and Nef proteins and also included the HIV long terminal 
repeat (LTR) promoter in the genome. The uptake measurements were carried out using the 
protocol described by Ibuki et al 42,43. Briefly, HeLa-env cells were seeded onto 6-well plates at 
2·105 cells/well and incubated under cell culture conditions for 24 hours in Dulbecco's modified 
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Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). The cells were then rinsed 
with phosphate-buffered saline (PBS), and replenished with 1 ml of FBS-free DMEM, 
containing either empty NPs or E1-FAM-NPs at a concentration of 36 µM, and incubated for 
predetermined time periods (1, 2, 4, 6 and 24 hours) at 37 ºC in 5% CO2. Next, the cells were 
detached from the dishes and washed gently with PBS at least three times to remove the NPs that 
had not been taken up. Single-cell suspensions for flow cytometry (FCM) were then prepared by 
the addition of 100 µl of trypsin/EDTA-PBS. Data acquisition was performed using the InCite™ 
software, where 10,000 events were recorded in the gated regions of interest assigned to the 
HeLa-env cells. 
To discriminate between attached and internalised E1-FAM-NPs, assays measuring 5(6)-FAM 
quenching by trypan blue were undertaken. 5(6)-FAM signal quenching occurs when trypan blue 
absorbs the light emitted by E1-FAM-NPs after excitation 44,45. The 5(6)-FAM signal of 
internalised E1-FAM-NPs is not quenched since trypan blue cannot pass the plasma membrane. 
Thus, the fluorescence remaining after trypan blue quenching is from the internalised E1-FAM-
NPs since only the extracellular fluorescence of E1-FAM-NPs is quenched. 
 
2.2.11.  Mucoadhesive potential of Nanoparticles 
In order to evaluate the mucoadhesive potential of E1NPs and Empty-NPs (GCNPs) a 
simulated fluid vaginal (SVF) was used, which had previously been developed and described by 
Owen and Katz 46. It contained sodium chloride (0.351 %), potassium hydroxide (0.14 %), 
calcium hydroxide (0.022 %), bovine serum albumin (0.0018 %), lactic acid (0.2 %), acetic acid 
(0.1 %), glycerol (0.016 %), urea (0.04 %), glucose (0.5 %). Mucin was added at a final 
concentration of 1.5 %(w/v) and mixed by sonication and vortexing.  
The experiments were performed following the protocol described by das Neves et al 16.  The 
Z-Ave changes of NPs were evaluated using a NPs suspension at a final concentration of 0.2 % 
v/v added in SVF without mucine (SVF/M-) and SVF with mucine (SVF/M+) (pH 4.2 and pH 
7.0). The pH was adjusted by adding minimum amount of hydrochloric acid or sodium 
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hydroxide. Samples were mixed by vortexing and left to equilibrate for 2 hours at 37 ºC before 
being measured for Z-Ave using a ZetaSizer Nano ZS. The GCNPs utilized presented a Z-Ave of 
273 ± 1.7 nm, PI value of 0.18 ± 0.01 and ζ of 19.8 ± 0.5 mV. 
 
2.2.12.  Ex vivo  studies  
The permeation assays of E1NPs were carried out using the vaginal mucosae of swine, 
obtained from the animal house at Bellvitge (University of Barcelona). This was done in 
accordance with the protocol approved by the Ethics Committee of the University of Barcelona47.   
Permeation studies were carried out following the protocol described in Ariza-Sáenz et al., 37. A 
mixture of receptor medium and Transcutol P® (80:20, v/v) was placed in the receptor 
compartment, each assay was performed in triplicate. 
To determine the permeated amount of E1 at specific time intervals over a period of 6 hours, 
300-μl aliquots were taken from the receptor chamber and immediately replaced with an equal 
volume of receptor medium. The apparent permeability coefficient (Papp, cm·s-1) of the mucosa was 
determined using the following equation: 




 ! · !! · !"
 (7) 
 
where Q is the total amount permeated at time t, ∆Q/∆t is the steady-step slope of the linear 
portion of the plot for the amount of peptide in the receptor compartment,  A is the exposed 
diffusion area and C0 is the initial concentration of peptide. 
Statistical comparisons between the samples were performed using one-way ANOVA and the 
Kruskal-Wallis test. Differences were considered significant at p < 0.05.  
 
To estimate the amount of E1 retained in the mucosa, a mixture of 1M PBS, pH 7.4, and 
acetonitrile (80:20, v/v) was used. The mucosal sample was then subjected to 20 minutes of cold 
sonication in an ultrasound bath. The amount of E1 retained was calculated taking into account 
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the recovery percentage (R). To determine R, a mucosal slice (non-treated) was weighed and 
incubated with a solution containing 100 µg/ml of E1 for 6 hours at 37 ºC. Both the amount of 
peptide remaining in solution and the mucosal weight were determined again at the end of the 







   (8) 
 
where 𝐶! is the amount (µg) of peptide extracted from the mucosa per 1 ml, m2 the mucosal 
slice weight at the end of the assay, m1 the mucosal slice weight at the beginning of the assay, 𝐶! 
the initial E1 concentration (100 µg/ml) and 𝐶! the E1 concentration obtained from the solution 
at the end of the assay. Results were the average of the three independent experiments. 
The E1 was quantified by HPLC/MS-MS, and it was expressed as μg / (g·cm2). The E1 
retained amount was calculated by the equation 9 43. 
 
𝑄! =  
!"!
!"
∕ 2.54 ·  !""
! 
  (9) 
 
where, 𝑄! is the E1 amount retained after the permeation assay through an area of 2.54 cm2. 
𝐸𝑥! is the E1 amount extracted. 𝑃𝑥 is the weight of each tissue sample.  
2.2.13.  In vivo  studies 
To determine the amount of E1 retained in the vaginal mucosa, experiments were conducted 
using four female swine weighing 25 kg each. Before carrying out the experiments, the animals 
were anaesthetized, and 1 ml aliquots of E1NPs or non-formulated E1 (0.425 mg/ml) were 
applied to the vaginal area. Non-formulated E1 was solubilised with 0.1% DMSO. After 4 hours 
of incubation, the animals were euthanized, and the intact vaginal mucosa was isolated by 
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excision with surgical scissors. The tissues were cut into slices of approximately 1 cm2. The 
extraction and quantification of the peptide were carried out as described above.  
 
3. RESULTS AND DISCUSSION 
3.1. Peptide synthesis 
E1 is an 18-mer peptide [WILEYLWKVPFDFWRGVI] with a MW of 2367 Da. It has 
amphipathic properties and shows significant HIV-1 inhibitory activity through binding to a 
highly conserved region on gp41 (the fusion peptide), which is essential for viral fusion to target 
cells 9. Thus, this peptide could be considered a putative microbicide because it may interact 
directly with HIV-1. It has been successfully synthesized, achieving a high degree of purity (> 
95%) after semi-preparative HPLC purification. The identity of E1 was confirmed by 
electrospray ionization mass spectrometry (ES-MS) in positive electro spray ionization (ESI) 
mode. Figure S1 (supplementary materials section), shows the mass spectrum of E1 with the 
most abundant ion at m/z 789.7 (z = 3). After E1 fragmentation, several transitions of different 
molecular weight were obtained and the product ion was at m/z 1189 (z = 2). In addition, the 
identity of E1 and E1-FAM was confirmed by MALDI-TOF spectrometry, and the E1 and E1-
FAM spectra are shown in Figures S2a and S2b (supplementary materials section), respectively. 
 
 3.2. Optimization of E1NPs 
The efficacy of drug delivery systems depends on their capacity to release a suitable drug 
concentration at the site of action. Consequently, we sought to achieve a high peptide entrapment 
rate. According to the results (Table S8 in supplementary material section), the lowest EE value 
was 13% and the highest was 86.4%, corresponding to F4 (factorial point). 
The encapsulation efficiency of E1P47 in nanoparticles was significantly influenced by all the 
three experimental factors investigated: peptide concentration (A), IAP volume (B) and polymer 
concentration (C). The response surface analysis of the obtained values led to the following 
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polynomial regression equation, which quantified the relationship between each of the significant 
parameters studied and the encapsulation efficiency: 
 
EE (%): -1183.0 + 2642.9 (X1) + 2756.2(X2) +546.9(X3) - 4834.0(X1)2 - 1694.6 (X2)2 - 321.1 (X3)2 
- 2437.2 (X1) (X2) + 1286.0 (X1)(X3) - 580.1 (X2)(X3)      (10) 
The Z-Ave and PI, which ranged from 176.0 to 443.8 nm and PI, which ranged from 0.06 to 
0.41, were mainly influenced by polymer concentration. Increasing the polymer concentration 
caused the Z-Ave and PI increase, while elevating the IAP volume led to smaller mean 
nanoparticles size and a decrease in the PI of nanoparticles. 
The analysis of the experimental scattering revealed a good reproducibility and proved the 
reliability of the double emulsion method: (Z-Ave 265-5 ± 1.8 nm and PI: 0.139 ± 0.04) (mean ± 
SD, n=3). The polynomial equations are given below (they quantify the relationship between Z-
Ave, the PI factor and the parameters studied): 
 
PI: 0.2 + 1.7 (X1) + 1.1(X2) - 1.6(X3) – 6.4(X1)2 – 1.1 (X2)2 – 1.04(X3)2 + 1.03(X1) (X2) + 1.4(X1) 
(X3) - 0.4 (X2) (X3)          (11) 
Z-Ave (nm): -352.9 + 3477.0 (X1) + 2025.1(X2) – 893.8(X3) – 6857.2(X1)2 – 1905.2(X2)2 + 
666.3(X3)2 - 382.5(X1) (X2) + 88.3(X1) (X3) – 108.5 (X2) (X3).     (12) 
The response surface plots of factors influencing the EE are represented in Figures 1a and 1b. 
Likewise, statistical analyses were performed to identify the effect of the factors on Z-Ave, EE 
and PI. (Table S9 shows the p values obtained from an ANOVA analysis in the Supplementary 
Material section).  
Chitosan has attracted a lot of attention as a biomedical material for in addition to the 
advantages described throughout this manuscript; this biopolymer has immune-stimulating 
biological, anti-tumor and anti-microbial activities, among others. However, the pharmaceutical 
applications related to Chitosan are limited by the compound’s insolubility at neutral or high pH 
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values 48. With the aim of overcoming the insolubility problems associated with a natural 
polymer, GC was used. This is chitosan (a natural polysaccharide composed of D-glucosamine 
and N-acetyl D-glucosamine units) conjugated with ethylene glycol. GC is water soluble at a pH 
below 7.0 and retains its positive charge at physiological pH values 49.  
 Therefore, the presence of GC increases NP mucoadhesiveness and retention times at the 
target site, and endows NPs with a positive surface charge. In addition, GC improves peptide 
transport across the epithelial barrier 50.  
Table 1. Physicochemical properties and EE of E1NPs and E1FAM-NPs 
Formulation Z-Ave (nm) ± SD PI ± SD ζ (mV) ± SD EE (%) 
E1-NPs  265.5 ±1.8 (a) 0.1 ± 0.04 (a) 28.0 ± 0.5 84.6 (a) 
E1FAM-NPs 316.3 ± 46.8 0.2 ± 0.02 32.3 ± 2.9 60.2 
(a) Values obtained from factorial design. Z-Ave, PI and ζ  values are average of three 
independent batches, and are expressed as mean ± SD. 
 
Although all three factors selected did affect the EE rates, the IAP volume and peptide 
concentration were the most critical factors (p > 0.05). The center values for IAP and peptide 
concentration were established as 0.5 ml and 1.5 mg/ml, respectively. While these values were 
maintained, EE rates were higher than 80 %. However, when the peptide concentration fell 
below the center value and the IAP volume rose above it, the EE rate decreased. 
Furthermore, with the objective of increasing the E1 encapsulation rate and decreasing the 
burst effect on the release, we studied the pH effect on the encapsulation efficiency. First, we 
studied the effect on the pH using values below the isoelectric point (PI) of the peptide (6.1), and 
we found that the encapsulation rate was not greater than 5.0 %, and therefore, we decided to use 
pH higher than this, thereby changing the charge distribution in the peptide and having a positive 
impact on the encapsulation. We also investigated the inner aqueous phase, as this might affect 




In previous studies we were able to determine the influence of the composition of the EE rates. 
The results obtained from these studies showed that a salt concentration above 50 % gave a 
higher encapsulation (EE) rate (around 80%). We put this rate down to the dehydration of the 
emulsifier molecules absorbed on the interface. This led to an increase in inner aqueous droplet 
size and thickening of the oil membrane 51. These effects may inhibit membrane rupture and 
increase the EE rate. Conversely, at a low salt concentration, the oil membrane became thinner 
and immediate rupture led to a loss of content. 
In the light of these findings, E1 was then dissolved in 50 % ACN/50mM Hepes (pH 7.4). The 
results showed that improvements had been achieved when there had been an accompanying 
increase in the volume of inner emulsion (a volume of 200 a 500 μl). 
The efficiency of the encapsulation of a peptide is highly dependent on the method used to 
prepare the NPs. The selection of a method that gives adequate drug encapsulation depends on 
the hydrophilicity of the active molecules. Many advantages are associated with the use of the 
double emulsion method, from which the systems obtained are versatile with respect to the 
different emulsifiers being employed. With the double emulsion, it is possible to prepare 
polymeric NPs, which allow the controlled release of the active soluble agent in the internal 
aqueous phase. Double emulsion is considered as an internal reservoir of trapped active 
(biomolecule) ingredients in an interior confined space, which protects the peptide from light, 
enzymatic degradation and oxidation. As for the disadvantages of double emulsion, it is a 
complex process and thermodynamically unstable. However, it is the unique chemical method 
which has the advantage of encapsulating both types of molecules, lipophilic and hydrophilic 52 
In order to overcome the disadvantages associated with traditional chemical methods, some 
authors approached this question with interesting new methods, such as electrohydrodynamic 
atomization (EHD)53, characterized by their simplicity, scalability and high versatility in the 
tailoring of the surface. Their multifunctionality enables the production of novel and functional 
materials. With regards to this, recently Parhizkar et al 54 described the fabrication of cisplatin-
loaded particles. These obtained high encapsulation rates, controlled release and the safety of the 
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pharmaceutical compound. This method might be considered as a promising tool for the 
encapsulation of antiretroviral agents and HIV-inhibitors in chitosan NPs, with nanosized 
particles with different and adjustable diameters 55. 
 
 3.3. Validation of optimized factors 
The results of the optimized dependent variables, such as Z-Ave (nm), PI and EE (%) were 
validated comparing them to the predicted results and what was actually observed. The 
differences between the predicted and the observed results were found to be from around 5 % 
and up to 9 % (one significant figure accuracy), as are shown in the table 1. The equation used to 
calculate the percentage residual value was: 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 = !"#$%&'#$ !"#$%&#!!"#$%&$' !"#$%&# 
!"#$%&'#$ !"!"#$!
 ×100 (11) 
 
The desirability of the optimized factor (EE) is shown in the chart. Usually, the desirability 
values fall within the range of 0 to 1, which means nearer the value is to zero (0), the less reliable 
it is. Whereas, the nearer to one (1) the value is, the more reliable the technique is. Our results 
demonstrate that the desirability reached the maximum value, which indicates the reliability the 
method. 
 
Table 2.  Validation of optimized factors. 
Response factor Predicted results Observed results Residual values (%) 
EE (%) 0.98 0.93 5.1 
Z-average (nm) 0.34 0.32 5.9 
PI 0.22 0.20 9.1 





















Figure 1. Response surface plots: (a) the effect of IAP and cPLGA on Z-Ave; (b) the effect of 
IAP and cPeptide on EE; (c) The surface response plot of desirability for optimization of EE 
factor. 
3.4. Physicochemical characterization of E1NPs  
To determine the physicochemical properties of the NPs, Z-Ave, PI and EE were measured. 
We also determined the physical status of the peptide inside the NPs and the stability of the 
suspension. 
3.5. X-Ray and FTIR studies 
By using the x-Ray and FTIR methods we were able to determine the physical state of the E1 







 X-Ray shows that PLGA, GC and E1 are of an amorphous nature. However, the X-Ray 
diffraction of PVA shows a reflection peak at 2θ = 19.7 º, characteristic of crystalline structure. 
Figure 2 shows X-ray diagrams of E1NPs and their compounds (PLGA, PVA, GC and E1). As 
can be seen, both the E1 peptide and the E1NPs shared a single weak bulge at 2θ = 15.97 º. 
Furthermore, an additional bulge was observed at 2θ = 19.82 º, corresponding to GC. The NPs 
profile was the same as the PLGA, E1 and GC profiles (Figure 2). Together, these observations 
indicate that the NPs pattern consisted of a combination of two structures. We did not detect the 
presence of nanocrystals as a consequence of peptide precipitation. 
 
 
Figure 2. X-ray diagrams: E1NPs and their compounds PLGA, GC, PVA and E1. In addition, to 
the bulges observed, we can see a prominent peak on the PVA graph, which in distinction to the 
rest of the compounds shows a crystalline profile. 
 
3.5.2. FTIR studies 
Figure 3 shows the FTIR spectra of E1, E1NPs and their components. Two prominent bands of 
the peptide (E1) backbone were present, one corresponding to the amide I band (1635.82 cm-1) 
and the other to the amide II band (1527.35 cm-1), both of which are shown in the figure. These 
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bands form the most sensitive spectral region of the secondary structure of proteins and 
polypeptides 56. The amide I band (1700-1600 cm-1) is mostly due to the C=O stretching vibration 
of the peptide bond. In the case of amide II, it mainly arises from in-plane NH bending and CN 
stretching. Amide A (3280 cm-1) is the least prominent but it is also related to NH stretching. The 
presence of bands between 1642 and 1624 cm−1 is assigned to the conformational structure of the 
β-sheet with contributions from β−turn structures, while the presence of bands between 1654 and 
1658 cm−1 is assigned to α-helix 57. Therefore, the results indicate that E1 presents a 
conformational type β structure with contributions from α-helix. These vibrational bands were 
repeated in the NPs with less intensity. In addition, E1NPs shared an additional band with PLGA 
(1762 cm-1) due to C-H stretching vibrations in the two polymer monomers 58. Another 
observation is that one can see the C–H broad alkyl stretching band (n = 2850-3000 cm-1) 
corresponding to the PVA compound. 
These results indicate that E1 has a conformational type β structure, characteristic of medium-
sized peptides. The results obtained from a circular dichroism analysis demonstrate that the 
peptide in the buffer presents a β-type conformation with contributions from β-turn and α-helix 9. 







Figure 3. FTIR spectra. This figure shows the FTIR spectra of E1NPs and their compounds: E1, 
PLGA 503H, PVA and GC.  
3.6. Transmission electron microscopy analysis 
The E1NP images obtained by TEM confirmed the Z-Ave and PI parameters obtained with the 
factorial design. In addition, the individual non-agglomerated, spherical NPs indicated that the 
nanoparticles did not aggregate in solution 59. Figure 4 clearly shows that the E1NPs were 
spherical with a polymer envelope and an inner cavity. 
 
 






3.7 .   In vitro  release studies 
The E1 release profile is given in Figure 5. At 20 hours the figures show the monophasic 
release profile of E1, which corresponds to 20 % of the total amount incorporated into the NPs.  
As E1 is an amphiphilic molecule, it would be erroneous to describe the entire release profile as 
monophasic, since NPs larger than 200 nm often exhibit a triphasic profile due to heterogeneous 
degradation 60–62. Although the E1 was not completely released from the NPs, the mechanism 
associated with release can be inferred. In general, there are four main release mechanisms: (a) 
diffusion through water-filled pores, (b) diffusion through the polymer, (c) erosion and (d) 
osmotic pumping 63. 
Table 3 shows the release constants and release exponents (n) calculated by fitting the release 
data into the respective equations along with regression coefficients (R2). On the basis of R2 
analysis, it could be concluded that the E1NPs followed the Korsmeyer Peppas model (figure 5). 
Data analysis for E1 released, according to the “Korsmeyer-Peppas” equation indicates the 
Fickian-diffusion release behaviour (n = 0.3; R2= 0.95) up to 20 hours. These findings can be 
explained by the swelling of the NPs and this can lead to the creation of fine pores through which 
the peptide can diffuse outwards. 
Table 3. Principal parameters obtained after fitting the release data from the E1NPs to different 
kinetic model equations 
Mathematical Models for E1NPs Parameters R2 
First order K1 : 0.3 0.78 
Higuchi KH: 0.2 0.93 
Korsmeyer Peppas Kk: 0.4; n : 0.3 0.95 





Figure 5. In vitro release of E1NPs. 
3.8. Stability Studies 
To determine the phenomena related to the physical destabilisation of the optimized 
formulation, the suspension was set aside and stored for 7 days at 4ºC. Assessment was 
performed using TurbiscanLab® and measurements were recorded for 24 hours. Variations 
greater than 10 %, either as a positive or negative value in the graphical scale of backscattering, 
are representative of an unstable formulation. Figure S3 in supplementary material section gives 
the backscattering profile of E1NPs. We did not observe any size changes, such as aggregation, 
coalescence or cremation, associated with physical destabilisation. The backscattering profile 
was within ± 2%, demonstrating that the formulation was stable under our experimental 
conditions. The E1NPs suspension may be stable in long-term storage. However, we limited our 
stability studies to a maximum time so that the NP conditions would be as previously mentioned 
before in each of the assessments carried out. 
 
3.9. Stability of E1 and E1NPs in human serum 
One of the main handicaps in the use of peptides in therapy is that they can easily be degraded 
by proteases, which render them with a short half-life in circulation and gives them poor 
bioavailability. One common strategy to overcome these obstacles is to protect them by the use 
of macromolecular carriers such as nanoparticles. 
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The aim of this assay was to study if the polymeric Nanoparticles (NPs) optimized in this work 
coated with glycol chitosan and which contain an HIV-1 fusion inhibitor peptide (E1) were able 
to protect the peptide by making them less accessible to the enzymes in a protease-rich media. 
To achieve this end, we incubated the free E1 peptide and the E1-NPs separately with human 
serum. Then aliquots were taken at different points in time. The supernatants were analysed by 
HPLC. A half-life of approximately 8 hours was obtained for the free E1 peptide. However, an 
enhanced stability was observed for the peptide entrapped in the NPs, the half-life being 
increased up to 24 h. In contrast, this improved stability in human serum could be explained by 
the slow release profile of the peptide from the NPs (figure 5). 
 
3.10. Uptake assays 
In order to conduct a flow cytometry analysis, NPs were prepared with E1-FAM, using the 
composition of the optimized formulation. The differences observed in the Z-Ave, PI, ζ and the 
EE of the E1-FAM-NPs, with respect to the E1-NPs, are attributed to the derivatization of E1 
with the fluorescent probes (5(6)-FAM).  These differences did not affect the cell studies as the 
values obtained were within the acceptable range for the studying of cell captures, and therefore 
it was not necessary to validate them (Table 1).  
Cell uptake of NPs is well-documented and has been used to evaluate cytotoxicity, cellular 
transport mechanisms and intracellular drug delivery 24,64,65 . In this study, cell uptake was assessed 
to discriminate between the NPs attached to the HeLa-env cell membrane and internalised NPs. 
HeLa-env cells were treated with E1FAM-NPs at 1, 2, 3, 4, 6 and 24 hours. The results obtained 
after treatment at 1 to 4 hours showed a time-dependent increase in intensity, while after 6 to 24 
hours of treatment, there was a sharp decrease in fluorescence intensity. Thus, in order to 
discriminate between attached and internalized NPs, HeLa-env cells were treated with E1FAM-
NPs and 0.1% TB for 1, 2, 4, 6 and 24 hours. During the first hours, approximately 53% of the 
NPs were internalised and the remainder (43% to 47%) were attributed to the fluorescence 
emitted by the NPs attached to the cell membrane (Figure 6a). 
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Figures 6b and 6c compare HeLa-env cells treated for 4 and 6 hours. At 4 hours, there was an 
increase in the intensity of side scatter (SS) and forward scatter (FS). However, side scatter and 
forward scatter intensities decreased over the following hours (6 hours). These two parameters 
have been used to evaluate both NP internalization and nanotoxicity. The increase in SS intensity 
represents an increase in granular content within cells due to possible cell uptake or apoptotic 
body formation. At the same time, the decrease in forward scatter intensity represents a reduction 
in cell size (they were in fact shrinking). This effect was attributed to constant uptake 
stimulation, which causes cell death. It has been demonstrated that living cells take up positively 
charged nanoparticles, disrupting lipid bilayers and eliciting nanoscale defects that enhance 
conductance through the plasmatic membrane 66. Once the particle stimulus is removed, cell 
integrity is recovered, whereas permanent stimulation destabilizes the plasmatic membrane and 
triggers apoptotic signals leading to cell death 67. 
As for the mechanism of NPs internalization, the surface charge, size and shape of these NPs 
are the critical factors that determine the cellular fate. It has been reported that polymeric NPs 
greater in size than 200 nm are easily taken into the cells via clathrin-dependent endocytosis 68. 
Other factors associated to the NPs can determine the path of the internalization that leads to the 
uptake. For example, it has been reported that biopolymers such as chitosan increase the uptake 
of NPs through endocytosis-mediated receptors 69.  
To date, several reports have discussed the internalization of polymeric nanoparticles into the 
cells. However, very little has been described on the methods used in the discrimination between 
NPs adhered to the external membrane and the NPs captured by any of the already well-known 
mechanisms. Following on along this line, in this study we aimed at determining the percentage 
of E1NPs that only adhere to the external cellular membrane using the trypan blue stain. We did 
this bearing in mind that the E1NPs were covered with Glycol Chitosan (GC), and this 
contributes to the positive superficial charge and strengthens the adherence of the NPs to the 
epithelial cells 69. With this straightforward technique one can make a distinction between those 
E1NPs, which are only “adhered”, and those, which are internalized. This information is core to 
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this study because the peptide released from the E1NPs adhered to the external membrane could 
inhibit the fusion of the HIV with the cells.  
 
3.11. The mucoadhesive potential of Nanoparticles 
The presence of glycoproteins in the cervical mucus (such as mucine) is the main cause of the 
electrostatic, hydrophobic and hydrogen bonding interactions with exogenous agents, such as the 
NPs 70. 
To evaluate the muco-adhesive potential of E1NPs and GCNPs, they were incubated with 
either SVF/M+ and SVF/M-. Higher increases in the Z-Ave for E1NPs and GCNPs were 
observed after incubation with SVF/M+. However, the Z-Ave experienced no changes when 
these were incubated with SVF/M-. These findings may be due to the electrostatic interactions 
between negative charges of the salicylic acid of mucine and positive charged amine groups of 
GC that cover the NPs (Figure 7).  
We observed that the hydrodynamic changes in GCNPs were higher than in E1NPs. This fact 
may be due to electrostatic repulsions between mucin and polypeptidic chains that might be 
adsorbed at the NPs surface.	
Likewise, we can observe, the NPs incubated with SVF/M+ at pH 7.0 were slightly larger 
compared to NPs incubated with SVF/M+ at pH 4.2. These relatively small variations may be 
attributed to an increase of mucin ionization at pH 7.0, and this in turn may to lead to a higher 




Figure 6. Cell uptake of E1FAM-NPs: (a) cell uptake kinetics of E1FAM-NPs; (b) fluorescence 
intensity of HeLa-env cells treated for 4 hours with E1FAM-NPs and 0.4% trypan blue dye (TP); 
(c) fluorescence intensity of HeLa-env cells treated for 6 hours. 
 
Figure 7. Increase in Z-Average of E1NPs and GCNPs after incubation with SVF with and 
without mucin at pH 4.0 and 7.0. Columns represent Z-Ave values and the bar standard deviation 
(n=3). 
 
3.12. Ex vivo  and in vivo  studies 
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One of the principal preoccupations was to determine the effectiveness of the potential 
protectiveness and the permeability of the NPs. The swine has been the animal most used to 
evaluate the permeation through the vaginal mucosa of different types of drugs.  
Porcine vaginal mucosa is widely used to evaluate drug permeation for either systemic or local 
action. Its anatomical, physiological and metabolic characteristics are similar to those of the 
human vagina, and thus it also has frequently been used to develop microbicides 71.  
However, swine is not a model for studying drug effectiveness as HIV infection does not occur 
in this animal 72. This is why in this study we focused on developing a release system that protects 
against degradation and maintains the HIV inhibitor stability, while at the same time the drug can 
be released into the vaginal mucosa without causing irritation or any toxicity. 
With respect to the evaluation of the effectiveness of the anti-HIV drug, the animals used so 
far can be classified into small animals and primates. SCID mice have been used and the results 
have been promising, though like the swine they do not experience natural infection. However, 
infection in transgenic rabbits has been established, with low levels of viral replication being 
detected, but only after the animal had been treated with different substances. Infection in 
chimpanzees and Rhesus monkeys has been limited due to the high costs, the scant availability of 
these animals and the lack of clinical symptoms. In the case of Rhesus monkeys, research is 
limited to studies on the HIV envelope and prospective vaccines based on TAT-HIV 73. 
 
3.12.1. Ex vivo  studies 
The intrinsic mechanisms of NP permeation can be elucidated by ex vivo assays 74. Diffusion 
mechanisms depend on the physicochemical properties of NPs, the chemical nature of the drug, 
the lipid/water partition coefficient and the degree of ionization in the molecules permeated 
through the epithelium. 
It has been demonstrated that the permeation of hydrophilic molecules through porcine vaginal 
mucosa is identical to that through human vaginal mucosa 75. Drug absorption through the vaginal 
mucosa occurs via a multi-way mechanism similar to that of biological membranes, and the main 
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diffusion mechanisms can be passive or active. Passive diffusion includes a transcellular route 
through the cell membranes, a paracellular route through the intercellular fluid and tight 
junctions. Active mechanisms generate gradients across the barriers, which are ATP dependent 76. 
The permeation coefficient value calculated for E1NPs and non-formulated E1 (Table 4) 
showed that the E1NPs were more permeable than non-formulated E1. An ANOVA analysis and 
the Kruskal-Wallis test revealed significant differences between the Papp obtained for E1NPs and 
non-formulated E1 (p < 0.05).  
These results suggest that the physicochemical characteristics of the NPs improved adherence 
to membranes and diffusion through the mucosa. The fact that there is an 8-fold increase in Papp 
in the peptide released by NPs may possibly be due to there being no hindrance factor to the 
penetration - such as a vaginal fluid- which would impede the E1NPs penetrating and going 
through the mucus. Therefore, the absence of vaginal fluid in the ex vivo assays made the 
penetration of E1NPs through the epithelium easier, and the amount quantified was the result of 
E1 release of the E1NPs that had penetrated by passive diffusion through the epithelium after 5 
hours of experiments. These assays lead to one being able to determine that the surrounding 
physiologic conditions of the vaginal mucosa, the secretions of fluids, the presence of 
glycosylated proteins and the bacteria are the main hindrance to the permeation of E1NPs. 
Another question is that due to its amphipathic nature, free-E1 could have acquired a 
secondary structure in cell membranes, which increases their binding. The formation of 
intramolecular hydrogen bonds in the membrane interface contributes to stronger binding 77. 
Thus, the peptide concentration in the upper layer of the mucosa increased, while the E1 
permeation rate was decreased. 
These findings allow us to conclude that the physiological conditions surrounding the vaginal 
mucosa, principally the mucine proteins which get tangled up with each other, cause very 
viscous mucus which prevent the penetration of biomolecules such as E1 69.  
 
Table 4. Papp values for E1 permeation of porcine vaginal mucosa after 6 hours. 
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 Paap (cm/s) (± SD) 
E1-NPs 8.9 x 10-3  (± 8.9 x 10-4) 
Non-Formulated E1 1.2 x 10-3  (± 3.2 x 10-4) 
Values were calculated as the mean ± standard deviation (± S.D).  
 
3.12.2. In vivo  studies 
Although in the ex vivo studies the conditions to obtain total dissolution of the drug present in 
the device can easily be established in the laboratory, the biological conditions in which the 
phenomenon occurs can only be analyzed in the laboratory through in vivo studies.  
In the case of the transport of macromolecules across the mucosa, this is principally 
determined by the histophysiological characteristics of the tissue and physiochemical properties 
of the molecule78. With respect to the vaginal fluid, the viscoelastic fluid (mucus) that lines the 
epithelium, in addition to acting as a protective barrier against pathogens and external agents, can 
also aid in the access of macromolecules (peptides, proteins, microbicides, etc) to the epithelium. 
The vaginal mucus is a fluid composed in the greatest part of glycoproteins (mucin), bacteria 
(lactobacillus) and water 79.  
The results obtained in the in vivo studies showed that the E1NPs were capable of interacting 
with the “mesh mucus” more easily than the non-formulated E1 (Table 5). These phenomena can 
be explained as a result of the inter-penetrations, which were sufficiently strong, between the 
polymer and the mucine chains, and which create a semi-permanent adhesiveness that facilitates 
the crossing of the NPs through the cervical mucus 80. 
The quantity retained (Qr) of formulated E1 that was detected after the treatment of the E1NPs, 
was significantly greater than the Qr of non-formulated E1 in the mucosa treated only with 
peptide. This can be put down to the presence of several enzymes in the mucosa, such as lactate 
dehydrogenase, alkaline phosphates, beta-glucuronidase and esterase. These are the leading 
causes of the enzymatic degradation of the peptide.  
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One explanation for the small quantity of non-formulated E1 which did find its way to the 
vaginal epithelium may be attributed to the fact that non-formulated E1 was solubilised with 
DMSO, which is considered a permeation enhancer 81 .  
The solubility of 100 % of the peptides of an amphiphilic nature requires organic solvents, 
such as ACN, to be used. In the case of E1 low concentration DMSO was selected to avoid 
harming the mucosa. It has been reported that in concentrations of DMSO above 60%, protein 
can be denatured and the intracellular conformation of the keratin can be changed. In the vaginal 
mucosa, at low concentrations, it is possible that DMSO interacts with the groups at the head of 
the lipid bilayer so as to distort the geometry of the packaging. This phenomenon can favour the 
additional partition of the peptide in the DMSO present in the tissue 82. 
From the results obtained from the in vivo studies we can conclude that the E1NPs were 
capable of penetrating the vaginal mucosa, reaching the epithelium and at this point releasing 
their content, thus protecting against the enzymatic degradation of the peptide. 
Together, the in vivo and ex vivo results highlight the important role of NPs in an effective, 
safe and protective delivery system for biomolecules such as peptides. They enable the almost 
impenetrable barrier of the mucosa (due to its lining) to be overcome.  
 




ug / (g·cm2) ± (SD) 
In vivo 
μg / (g·cm2) ± (SD) 
E1-NPs 38.6 ± 1.6 0.7 ± 0.17 
Non-Formulated E1 89.9 ± 2.1 0.4 ± 0.02 
Values were calculated as the mean ± standard deviation (± S.D). 
 
4.  CONCLUSIONS.  
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In this paper we have presented a novel strategy to fight the spread of HIV-1 based on 
polymeric NPs loaded with an HIV-1 fusion inhibitor peptide (E1NPs). The NPs were optimized 
and characterized to incorporate and release an HIV-1 fusion inhibitor peptide (E1) in porcine 
vaginal mucosa. 
The most important aspects in the development of the NPs, both the modifications made in the 
method of double emulsion and the selection of the most relevant factors employed in the design 
and manufacture of the E1NPs, were the over-riding concerns in the development of the NPs so 
that they had optimum physio-chemical and morphological properties for the encapsulation and 
release of E1. The results obtained from the analysis of FTIR and X-ray, and the results on 
physical and chemical stability of the E1 encapsulated in the NPs demonstrate that there were no 
interactions between the components of the formulation, nor changes in the structure of the E1, 
nor secondary reactions that could lead to the peptide losing bioactivity.   
Our ex vivo studies confirmed that NP were able to permeate the vaginal tissue. Despite assay 
constraints, such as a restricted permeation area, absence of vaginal fluid and an inactive 
metabolism, we conclude that E1NPs permeate the mucosa more easily than the non-formulated 
peptide.  
From our in vivo studies, we are able to conclude that the E1NPs cross the vaginal fluid to 
reach the epithelium and release the peptide inside. Although a small amount of peptide was 
extracted from the mucosa treated with non-formulated E1, this finding may be attributed to the 
presence of DMSO in the solution, which is known to be a permeation enhancer, and therefore 
does not invalidate our findings.    
In addition, we believe that non-formulated E1 might have been partially hydrolysed by 
enzymes present in the mucus and this is the reason why a small quantity was able to reach the 
epithelium. 
Owing to their physio-chemical, morphological and muco-adhesive properties, and their 
stability, the E1NPs presented in this study can be considered as a useful platform in the 
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